SLC39A6 and breast cancer: When the Nottingham cohort was classified into four groups based on the combination of SLC39A6 nuclear and cytoplasmic expression: (nuclear low/cytoplasmic low), (nuclear high/cytoplasmic low), (nuclear high/cytoplasmic high) and (nuclear low/cytoplasmic high), the (nuclear high/cytoplasmic high) group showed better BCSS in comparison to all other subgroups in both the entire BC cohort (P = 0.010) and in the ER + subgroup (P = 0.014; Fig. 3).